{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:54:50Z","timestamp":1790985290836,"version":"4.1.0"},"reference-count":61,"publisher":"e-Century Publishing Corporation","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/zswv1767","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T05:18:10Z","timestamp":1730351890000},"page":"4788-4802","source":"Crossref","is-referenced-by-count":4,"title":["Cabozantinib inhibits tumor growth in mice with ovarian cancer"],"prefix":"10.62347","volume":"14","author":[{"given":"Patrick J","family":"Stiff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M and Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin 2019; 69: 280-304.","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Liu L and Xiong W. Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2021; 100: e26849.","DOI":"10.1097\/MD.0000000000026849"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12032-017-0960-z","article-title":"A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer","volume":"34","author":"Oronsky","year":"2017","unstructured":"Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA and Cottrill HM. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol 2017; 34: 103.","journal-title":"Med Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2020.07.008","article-title":"Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990-2017","volume":"159","author":"Zheng","year":"2020","unstructured":"Zheng L, Cui C, Shi O, Lu X, Li YK, Wang W, Li Y and Wang Q. Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990-2017. Gynecol Oncol 2020; 159: 239-247.","journal-title":"Gynecol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"100629","DOI":"10.1016\/j.ctarc.2022.100629","article-title":"Epithelial ovarian cancer: review article","volume":"33","author":"Sambasivan","year":"2022","unstructured":"Sambasivan S. Epithelial ovarian cancer: review article. Cancer Treat Res Commun 2022; 33: 100629.","journal-title":"Cancer Treat Res Commun"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN and Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74: 12-49.","journal-title":"CA Cancer J Clin"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40425-015-0051-7","article-title":"Immunotherapeutic approaches to ovarian cancer treatment","volume":"3","author":"Chester","year":"2015","unstructured":"Chester C, Dorigo O, Berek JS and Kohrt H. Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer 2015; 3: 7.","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","unstructured":"Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V and Gulley JL. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol 2019; 5: 393-401.","journal-title":"JAMA Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/intimm\/dxw020","article-title":"Immune checkpoint inhibition in ovarian cancer","volume":"28","author":"Hamanishi","year":"2016","unstructured":"Hamanishi J, Mandai M and Konishi I. Immune checkpoint inhibition in ovarian cancer. Int Immunol 2016; 28: 339-348.","journal-title":"Int Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"12067","DOI":"10.3390\/ijms232012067","article-title":"Focus on PD-1\/PD-L1 as a therapeutic target in ovarian cancer","volume":"23","author":"Dumitru","year":"2022","unstructured":"Dumitru A, Dobrica EC, Croitoru A, Cretoiu SM and Gaspar BS. Focus on PD-1\/PD-L1 as a therapeutic target in ovarian cancer. Int J Mol Sci 2022; 23: 12067.","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O’Byrne K and Kulasinghe A. Immune checkpoint inhibitors in cancer therapy. Curr Oncol 2022; 29: 3044-3060.","journal-title":"Curr Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"UA","year":"2019","unstructured":"Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J and Ledermann JA. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol 2019; 30: 1080-1087.","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Walsh CS, Kamrava M, Rogatko A, Kim S, Li A, Cass I, Karlan B and Rimel BJ. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. PLoS One 2021; 16: e0252665.","DOI":"10.1371\/journal.pone.0252665"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","unstructured":"Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ and Odunsi K. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol 2021; 7: 78-85.","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13048-021-00862-5","article-title":"Efficacy of PD-1\/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis","volume":"14","author":"Zhu","year":"2021","unstructured":"Zhu J, Yan L and Wang Q. Efficacy of PD-1\/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis. J Ovarian Res 2021; 14: 112.","journal-title":"J Ovarian Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1084887","DOI":"10.3389\/fimmu.2023.1084887","article-title":"Towards a consensus definition of immune exclusion in cancer","volume":"14","author":"Tiwari","year":"2023","unstructured":"Tiwari A, Oravecz T, Dillon LA, Italiano A, Audoly L, Fridman WH and Clifton GT. Towards a consensus definition of immune exclusion in cancer. Front Immunol 2023; 14: 1084887.","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Clifton GT, Rothenberg M, Ascierto PA, Begley G, Cecchini M, Eder JP, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai SI, Provenzano P, Pure E, Ribas A, Schalper KA and Fridman WH. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. J Immunother Cancer 2023; 11: e006773.","DOI":"10.1136\/jitc-2023-006773"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the TUMOR INFLAMMATION SIgnature (TIS): results from The Cancer Genome Atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","unstructured":"Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, Wallden B, Marincola FM and Cesano A. Pan-cancer adaptive immune resistance as defined by the TUMOR INFLAMMATION SIgnature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer 2018; 6: 63.","journal-title":"J Immunother Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A and McClanahan TK. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 2017; 127: 2930-2940.","journal-title":"J Clin Invest"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to anti-PD cancer immunotherapy","volume":"40","author":"MD","year":"2022","unstructured":"Vesely MD, Zhang T and Chen L. Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol 2022; 40: 45-74.","journal-title":"Annu Rev Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3390\/ijms23052847","article-title":"Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment","volume":"23","author":"Dobosz","year":"2022","unstructured":"Dobosz P, Stepien M, Golke A and Dzieciatkowski T. Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment. Int J Mol Sci 2022; 23: 2847.","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2147\/OTT.S155425","article-title":"First-line treatment of women with advanced ovarian cancer: focus on bevacizumab","volume":"12","author":"Marchetti","year":"2019","unstructured":"Marchetti C, Muzii L, Romito A and Benedetti Panici P. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. Onco Targets Ther 2019; 12: 1095-1103.","journal-title":"Onco Targets Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/ijgc-2022-003941","article-title":"Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer","volume":"33","author":"Andrikopoulou","year":"2023","unstructured":"Andrikopoulou A, Liontos M, Skafida E, Koutsoukos K, Apostolidou K, Kaparelou M, Rouvalis A, Bletsa G, Dimopoulos MA and Zagouri F. Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer. Int J Gynecol Cancer 2023; 33: 571-576.","journal-title":"Int J Gynecol Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.critrevonc.2018.08.011","article-title":"The Era of PARP inhibitors in ovarian cancer: “class action” or not? A systematic review and meta-analysis","volume":"131","author":"Staropoli","year":"2018","unstructured":"Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cuce M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P and Tagliaferri P. The Era of PARP inhibitors in ovarian cancer: “class action” or not? A systematic review and meta-analysis. Crit Rev Oncol Hematol 2018; 131: 83-89.","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP Inhibitors in ovarian cancer: a review","volume":"18","author":"O&#x2019","year":"2023","unstructured":"O’Malley DM, Krivak TC, Kabil N, Munley J and Moore KN. PARP Inhibitors in ovarian cancer: a review. Target Oncol 2023; 18: 471-503.","journal-title":"Target Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"104230","DOI":"10.1016\/j.critrevonc.2023.104230","article-title":"Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: a systematic review and meta-analysis","volume":"194","author":"Wang","year":"2024","unstructured":"Wang Y, Liu L, Jin X and Yu Y. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2024; 194: 104230.","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Zhu Y, Lin Y, Liu K and Zhu H. Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis. J Gynecol Oncol 2024; [Epub ahead of print].","DOI":"10.3802\/jgo.2024.35.e71"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"17588359221107112","DOI":"10.1177\/17588359221107112","article-title":"Cabozantinib for the treatment of solid tumors: a systematic review","volume":"14","author":"Maroto","year":"2022","unstructured":"Maroto P, Porta C, Capdevila J, Apolo AB, Viteri S, Rodriguez-Antona C, Martin L and Castellano D. Cabozantinib for the treatment of solid tumors: a systematic review. Ther Adv Med Oncol 2022; 14: 17588359221107112.","journal-title":"Ther Adv Med Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/14737140.2021.1919090","article-title":"Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence","volume":"21","author":"Santoni","year":"2021","unstructured":"Santoni M, Iacovelli R, Colonna V, Klinz S, Mauri G and Nuti M. Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. Expert Rev Anticancer Ther 2021; 21: 1029-1054.","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC and Joly AH. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10: 2298-308.","journal-title":"Mol Cancer Ther"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M and Yu Y. Targeting tyrosine kinases in ovarian cancer: small molecule inhibitor and monoclonal antibody, where are we now? Biomedicines 2022; 10: 2113.","DOI":"10.3390\/biomedicines10092113"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/ijc.24028","article-title":"Functional significance of VEGFR-2 on ovarian cancer cells","volume":"124","author":"Spannuth","year":"2009","unstructured":"Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM and Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 2009; 124: 1045-53.","journal-title":"Int J Cancer"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling - in control of vascular function","volume":"7","author":"Olsson","year":"2006","unstructured":"Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-71.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Masoumi Moghaddam S, Amini A, Morris DL and Pourgholami MH Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 2012; 31: 143-62.","DOI":"10.1007\/s10555-011-9337-5"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ygyno.2012.05.002","article-title":"VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5","volume":"127","author":"Herr","year":"2012","unstructured":"Herr D, Sallmann A, Bekes I, Konrad R, Holzheu I, Kreienberg R and Wulff C. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol Oncol 2012; 127: 210-6.","journal-title":"Gynecol Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-22-0873","article-title":"FDA approval summary: cabozantinib for differentiated thyroid cancer","volume":"28","author":"Duke","year":"2022","unstructured":"Duke ES, Barone AK, Chatterjee S, Mishra-Kalyani PS, Shen YL, Isikwei E, Zhao H, Bi Y, Liu J, Rahman NA, Wearne E, Leighton JK, Stephenson M, Ojofeitimi I, Scepura B, Nair A, Pazdur R, Beaver JA and Singh H. FDA approval summary: cabozantinib for differentiated thyroid cancer. Clin Cancer Res 2022; 28: 4173-4177.","journal-title":"Clin Cancer Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40267-018-0547-6","article-title":"Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use","volume":"34","author":"Lyseng-Williamson","year":"2018","unstructured":"Lyseng-Williamson KA. Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use. Drugs Ther Perspect 2018; 34: 457-465.","journal-title":"Drugs Ther Perspect"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1136\/gutjnl-2020-320716","article-title":"Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma","volume":"70","author":"Shang","year":"2021","unstructured":"Shang R, Song X, Wang P, Zhou Y, Lu X, Wang J, Xu M, Chen X, Utpatel K, Che L, Liang B, Cigliano A, Evert M, Calvisi DF and Chen X. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut 2021; 70: 1746-1757.","journal-title":"Gut"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ejca.2017.06.018","article-title":"A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma","volume":"83","author":"Vergote","year":"2017","unstructured":"Vergote IB, Smith DC, Berger R, Kurzrock R, Vogelzang NJ, Sella A, Wheler J, Lee Y, Foster PG, Weitzman R and Buckanovich RJ. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. Eur J Cancer 2017; 83: 229-236.","journal-title":"Eur J Cancer"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ygyno.2018.12.008","article-title":"A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: an NRG oncology\/gynecologic oncology group study","volume":"152","author":"Matulonis","year":"2019","unstructured":"Matulonis UA, Sill MW, Makker V, Mutch DG, Carlson JW, Darus CJ, Mannel RS, Bender DP, Crane EK and Aghajanian C. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: an NRG oncology\/gynecologic oncology group study. Gynecol Oncol 2019; 152: 548-553.","journal-title":"Gynecol Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.bulcan.2021.05.005","article-title":"New EMA approval: nivolumab plus cabozantinib for advanced renal clear cell carcinoma","volume":"108","author":"Naoun","year":"2021","unstructured":"Naoun N and Vano YA. New EMA approval: nivolumab plus cabozantinib for advanced renal clear cell carcinoma. Bull Cancer 2021; 108: 991-993.","journal-title":"Bull Cancer"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11912-018-0740-8","article-title":"Combination immune checkpoint blockade strategies to maximize immune response in gynecological cancers","volume":"20","author":"Liu","year":"2018","unstructured":"Liu YL and Zamarin D. Combination immune checkpoint blockade strategies to maximize immune response in gynecological cancers. Curr Oncol Rep 2018; 20: 94.","journal-title":"Curr Oncol Rep"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","article-title":"Development of a syngeneic mouse model for events related to ovarian cancer","volume":"21","author":"Roby","year":"2000","unstructured":"Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG and Terranova PF. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21: 585-591.","journal-title":"Carcinogenesis"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1746-1596-7-42","article-title":"Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring","volume":"7","author":"Rizzardi","year":"2012","unstructured":"Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP, Metzger GJ and Schmechel SC. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 2012; 7: 42.","journal-title":"Diagn Pathol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3390\/ijms23031833","article-title":"Granzymes: the molecular executors of immune-mediated cytotoxicity","volume":"23","author":"Hay","year":"2022","unstructured":"Hay ZLZ and Slansky JE. Granzymes: the molecular executors of immune-mediated cytotoxicity. Int J Mol Sci 2022; 23: 1833.","journal-title":"Int J Mol Sci"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.3390\/cancers14246257","article-title":"Kinase inhibitors in the treatment of ovarian cancer: current state and future promises","volume":"14","author":"Skorda","year":"2022","unstructured":"Skorda A, Bay ML, Hautaniemi S, Lahtinen A and Kallunki T. Kinase inhibitors in the treatment of ovarian cancer: current state and future promises. Cancers (Basel) 2022; 14: 6257.","journal-title":"Cancers (Basel)"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"69903","DOI":"10.18632\/oncotarget.12065","article-title":"Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers","volume":"7","author":"Linklater","year":"2016","unstructured":"Linklater ES, Tovar EA, Essenburg CJ, Turner L, Madaj Z, Winn ME, Melnik MK, Korkaya H, Maroun CR, Christensen JG, Steensma MR, Boerner JL and Graveel CR. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. Oncotarget 2016; 7: 69903-69915.","journal-title":"Oncotarget"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance mechanisms to anti-angiogenic therapies in cancer","volume":"10","author":"Haibe","year":"2020","unstructured":"Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S and Shamseddine A. Resistance mechanisms to anti-angiogenic therapies in cancer. Front Oncol 2020; 10: 221.","journal-title":"Front Oncol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12935-018-0530-2","article-title":"Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma","volume":"18","author":"Lai","year":"2018","unstructured":"Lai Y, Zhao Z, Zeng T, Liang X, Chen D, Duan X, Zeng G and Wu W. Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma. Cancer Cell Int 2018; 18: 31.","journal-title":"Cancer Cell Int"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Kather JN, Suarez-Carmona M, Charoentong P, Weis CA, Hirsch D, Bankhead P, Horning M, Ferber D, Kel I, Herpel E, Schott S, Zornig I, Utikal J, Marx A, Gaiser T, Brenner H, Chang-Claude J, Hoffmeister M, Jager D and Halama N. Topography of cancer-associated immune cells in human solid tumors. Elife 2018; 7: e36967.","DOI":"10.7554\/eLife.36967"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1758835920967241","DOI":"10.1177\/1758835920967241","article-title":"Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis","volume":"12","author":"Hao","year":"2020","unstructured":"Hao J, Yu H, Zhang T, An R and Xue Y. Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis. Ther Adv Med Oncol 2020; 12: 1758835920967241.","journal-title":"Ther Adv Med Oncol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/eji.201646837","article-title":"CD69: from activation marker to metabolic gatekeeper","volume":"47","author":"Cibrian","year":"2017","unstructured":"Cibrian D and Sanchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol 2017; 47: 946-953.","journal-title":"Eur J Immunol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"867098","DOI":"10.3389\/fimmu.2022.867098","article-title":"Escaping death: how cancer cells and infected cells resist cell-mediated cytotoxicity","volume":"13","author":"Tuomela","year":"2022","unstructured":"Tuomela K, Ambrose AR and Davis DM. Escaping death: how cancer cells and infected cells resist cell-mediated cytotoxicity. Front Immunol 2022; 13: 867098.","journal-title":"Front Immunol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-gamma in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L and Zhang Y. Roles of IFN-gamma in tumor progression and regression: a review. Biomark Res 2020; 8: 49.","journal-title":"Biomark Res"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Jiang T, Zhou C and Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology 2016; 5: e1163462.","DOI":"10.1080\/2162402X.2016.1163462"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.it.2023.09.003","article-title":"IL-2-driven CD8(+) T cell phenotypes: implications for immunotherapy","volume":"44","author":"Niederlova","year":"2023","unstructured":"Niederlova V, Tsyklauri O, Kovar M and Stepanek O. IL-2-driven CD8(+) T cell phenotypes: implications for immunotherapy. Trends Immunol 2023; 44: 890-901.","journal-title":"Trends Immunol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nature04651","article-title":"Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction","volume":"440","author":"Castellino","year":"2006","unstructured":"Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C and Germain RN. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006; 440: 890-5.","journal-title":"Nature"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/1744666X.2017.1384313","article-title":"Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3","volume":"13","author":"Schaller","year":"2017","unstructured":"Schaller TH, Batich KA, Suryadevara CM, Desai R and Sampson JH. Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. Expert Rev Clin Immunol 2017; 13: 1049-1060.","journal-title":"Expert Rev Clin Immunol"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Allen F, Bobanga ID, Rauhe P, Barkauskas D, Teich N, Tong C, Myers J and Huang AY. CCL3 augments tumor rejection and enhances CD8(+) T cell infiltration through NK and CD103(+) dendritic cell recruitment via IFNgamma. Oncoimmunology 2017; 7: e1393598.","DOI":"10.1080\/2162402X.2017.1393598"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG and Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 2018; 15: 325-340.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/10\/ajcr0158631.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:00:22Z","timestamp":1766023222000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/10\/ajcr0158631.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/zswv1767","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}